Asklepion Pharmaceuticals, LLC

Asklepion Pharmaceuticals is a specialty biopharmaceutical company founded in 2006 and headquartered in Baltimore, Maryland. The company is focused on the discovery, development, and commercialization of pharmaceutical products to help patients who have little to no therapeutic options, particularly pediatric patients with rare diseases and critical conditions. Asklepion operates with a lean, specialized team dedicated to developing innovative therapies for unmet medical needs in the pediatric rare disease space. The company's primary focus is on developing treatment options for children with rare and critical conditions that often lack adequate therapeutic alternatives. Asklepion has successfully brought one drug to FDA approval (Cholbam/cholic acid) and maintains an active pipeline with its lead candidate, intravenous L-citrulline, currently in Phase 3 clinical development for the prevention of acute lung injury in pediatric cardiac surgery patients.